Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX®, the First and Only Gene Therapy for Hemophilia B
Hemophilia B, also known as Christmas disease or factor IX deficiency, is a rare, degenerative disease that occurs in approximately 1 in 25,000 male births.
- Hemophilia B, also known as Christmas disease or factor IX deficiency, is a rare, degenerative disease that occurs in approximately 1 in 25,000 male births.
- "We are deeply grateful to be selected by CSL Behring as a trusted partner to provide the first gene therapy for patients with hemophilia B," said Brandon Tom, Orsini's Chief Executive Officer.
- Our experienced, compassionate Hemophilia Care Team is fully committed to working with payors and providers to ensure patients receive access to this life-changing therapy."
- Providing patients with comprehensive and compassionate care since 1987, Orsini is a leading independent specialty pharmacy focused on rare diseases and gene therapies.